EGFR and non-small cell lung carcinoma: BLU-945, an inhibitor targeting EGFR+/T790M and EGFR+/T790M/C797S resistance mutations, is currently undergoing phase I/II clinical trials for the treatment of EGFR-driven NSCLC that has acquired resistance[51,52].